Diagnostic Criteria for Acute Alcoholic Hepatitis

Core Diagnostic Elements

• The American Association for the Study of Liver Diseases recommends that acute alcoholic hepatitis is diagnosed by the rapid onset of jaundice with characteristic laboratory findings occurring after heavy alcohol use within the past 60 days, often accompanied by tender hepatomegaly and signs of hepatic decompensation 1, 2, 3
• The American College of Gastroenterology suggests that rapid onset of jaundice is the cardinal feature, with serum bilirubin typically >3 mg/dL 1, 2, 3
• Tender hepatomegaly on physical examination is commonly present, according to the American Association for the Study of Liver Diseases 1, 3
• Fever may occur even without infection, as noted by the European Association for the Study of the Liver 2
• Hepatic decompensation including ascites, encephalopathy, bacterial infection, or variceal bleeding frequently accompanies the presentation, as stated by the American Association for the Study of Liver Diseases 1, 3

Laboratory Criteria

• The American Association for the Study of Liver Diseases recommends that AST elevation >50 IU/mL but rarely exceeding 400 IU/mL is a diagnostic criterion for acute alcoholic hepatitis 1, 2, 3
• The AST/ALT ratio >1.5 is a key diagnostic feature, with ratios <1.5 seen in <2% of histologically proven cases, according to the American College of Gastroenterology 1, 3
• Elevated bilirubin >3 mg/dL is a common finding, as noted by the European Association for the Study of the Liver 1, 2, 3
• Neutrophilia is frequently present, according to the European Association for the Study of the Liver 2

Diagnostic Classification System

• The American Association for the Study of Liver Diseases defines definite alcoholic hepatitis as clinical diagnosis plus liver biopsy confirmation 1, 3
• Probable alcoholic hepatitis is defined as clinical diagnosis with typical presentation and laboratory findings without confounding factors, according to the American College of Gastroenterology 1, 3

Special Considerations in Cirrhotic Patients

• The American Association for the Study of Liver Diseases notes that patients with undiagnosed or known cirrhosis may decompensate due to superimposed alcoholic hepatitis, presenting as acute-on-chronic liver failure 1, 3
• Asymptomatic histologic alcoholic steatohepatitis may coexist with cirrhosis in 30-40% of patients, as stated by the American Association for the Study of Liver Diseases 1, 3

Severity Assessment

• The Maddrey Discriminant Function (mDF) ≥32 defines severe alcoholic hepatitis and is the threshold for initiating specific therapy, according to the American College of Gastroenterology 4, 5, 2
• The MELD score >20 indicates severe disease, as noted by the American Association for the Study of Liver Diseases 6

Exclusion of Alternative Diagnoses

• Imaging must exclude biliary obstruction, according to the American College of Gastroenterology 1, 3
• Testing for viral hepatitis, severe autoimmune liver disease, and Wilson disease is necessary, as stated by the American Association for the Study of Liver Diseases 1, 3

Diagnosing Acute Alcoholic Hepatitis Superimposed on Chronic Liver Disease

Diagnostic Criteria and Assessment

• The American Association for the Study of Liver Diseases recommends identifying underlying cirrhosis through imaging findings, such as liver dysmorphy, portal-systemic collaterals, splenomegaly, caudate lobe hypertrophy, and posterior hepatic notch visualization, as well as clinical stigmata and laboratory markers, including thrombocytopenia, hypoalbuminemia, and prolonged INR 7, 8
• The European Association for the Study of the Liver suggests that liver biopsy should be strongly considered in scenarios with atypical presentation or history, confounding factors, or when aggressive treatment with significant risk is contemplated, and that the transjugular approach is preferred due to frequent coagulopathy and ascites in these patients 8, 9
• The presence of macrovesicular steatosis plus at least one of neutrophil infiltration, hepatocyte ballooning, or Mallory-Denk bodies is required for definite alcoholic hepatitis, with additional features that may be present including perivenular and pericellular fibrosis, lobular inflammation, and cholestatic changes 7, 10
• Studies have shown that histologic confirmation is only present in 70-80% of patients with clinically presumed acute alcoholic hepatitis, meaning clinical diagnosis alone carries a 10-50% risk of misclassification 7, 8, 9

Severity Assessment and Prognostic Scoring

• The Maddrey Discriminant Function (MDF) score ≥32 defines severe disease requiring treatment consideration, while the MELD score >20-21 indicates severe disease with high 90-day mortality 7, 10
• The Lille score (on day 7 of treatment) ≥0.45 indicates non-responders, and the CLIF-C OFS (Consortium Organ Failure Score) is used for prognostication in the context of acute-on-chronic liver failure 8, 9

Diagnostic Criteria and Management of Alcoholic Hepatitis

Introduction to Alcoholic Hepatitis Diagnosis

• The American Association for the Study of Liver Diseases recommends that liver biopsy is not necessary for routine diagnosis but should be strongly considered in specific scenarios, such as atypical presentation or history, confounding factors present, or when aggressive treatment with significant risk is contemplated 11
• Histologic confirmation is only present in 70-80% of patients with clinically presumed acute alcoholic hepatitis, meaning clinical diagnosis alone carries a 10-50% risk of misclassification 11

Exclusion of Alternative Diagnoses

• The National Institute of Diabetes and Digestive and Kidney Diseases suggests systematically excluding alternative diagnoses, including biliary obstruction via imaging, viral hepatitis, severe autoimmune liver disease, Wilson disease, drug-induced liver injury, and hepatocellular carcinoma 12

Severity Assessment and Prognostic Scoring

• The American Association for the Study of Liver Diseases recommends calculating prognostic scores, such as the Maddrey Discriminant Function (mDF) and MELD score, to identify severe disease 12
• A mDF ≥32 defines severe alcoholic hepatitis requiring treatment consideration, and is associated with 30-50% 28-day mortality without treatment 12
• A MELD >20-21 indicates severe disease with high 90-day mortality 12
• The Lille score, calculated on day 7 of corticosteroid treatment, can predict response to treatment, with a score ≥0.45 indicating non-responders who should discontinue steroids 12

Treatment Eligibility Assessment

• The American Association for the Study of Liver Diseases recommends screening for contraindications, including uncontrolled infections, acute kidney injury, uncontrolled upper gastrointestinal bleeding, and concomitant diseases, before proceeding with treatment eligibility screening 12
• For patients with mDF ≥32 or MELD >20, treatment eligibility screening should include assessment for contraindications and consideration of referral for early liver transplantation or palliative care as clinically appropriate 12

Management for Severe Disease

• The American Association for the Study of Liver Diseases recommends starting prednisolone 40 mg daily or equivalent with or without IV N-acetylcysteine for patients with severe disease 12
• Enteral nutrition with a goal of >21 kcal/kg (or 30-40 kcal/kg/day with 1.0-1.5 g protein/kg/day) should be implemented, and consideration of referral for early liver transplantation or palliative care as clinically appropriate 12

Management for Non-Severe Disease

• The American Association for the Study of Liver Diseases recommends alcohol abstinence as the single most effective intervention for long-term survival in patients with non-severe disease 11
• Abstinence can result in normalization of liver enzymes and improved clinical features even in cirrhosis, and initiation of abstinence counseling immediately is recommended 11

Differentiating Alcoholic Hepatitis from Acute-on-Chronic Liver Failure (ACLF)

Introduction to Alcoholic Hepatitis and ACLF

• The American Association for the Study of Liver Diseases recommends that alcoholic hepatitis can exist as a distinct clinical entity or serve as the precipitating event that triggers ACLF, with the key distinction being the presence of extrahepatic organ failures 13, 14
• Severe alcoholic hepatitis (sAH) is defined by rapid onset jaundice, AST >50 IU/mL, AST/ALT ratio >1.5, recent heavy alcohol use, and Maddrey Discriminant Function ≥32 or MELD >20, according to the European Association for the Study of the Liver 15

Diagnosis and Classification

• The presence and number of extrahepatic organ failures determines whether a patient has isolated alcoholic hepatitis versus ACLF, as stated by the American College of Gastroenterology 13, 14
• ACLF requires three minimum components: acute deterioration in clinical condition, liver failure, and at least one extrahepatic organ failure, as defined by the European Association for the Study of the Liver 16
• Severe alcoholic hepatitis is the precipitating event for ACLF in approximately 30-57% of Western ACLF cases, according to the American Association for the Study of Liver Diseases 17, 18

Organ Failure Assessment

• The CLIF-SOFA criteria are used to assess for extrahepatic organ failures, including liver, coagulation, kidney, brain, circulation, and respiration, as recommended by the European Association for the Study of the Liver 13
• Kidney failure is defined as creatinine ≥2.0 mg/dL, and brain failure is defined as Grade III-IV hepatic encephalopathy, according to the American College of Gastroenterology 13, 17

Prognosis and Management

• Patients with severe alcoholic hepatitis who develop ACLF have dramatically worse outcomes, with 28-day mortality ranging from 31% to 72%, as stated by the American Association for the Study of Liver Diseases 13, 17
• ICU admission is required for close monitoring and organ support in patients with severe alcoholic hepatitis and ACLF, according to the European Association for the Study of the Liver 13
• Early liver transplantation evaluation is critical in patients with severe alcoholic hepatitis and ACLF, as recommended by the American College of Gastroenterology 13

Guideline for Diagnosing Acute Alcoholic Hepatitis in Patients with Cirrhosis

Diagnostic Classification (American Association for the Study of Liver Diseases)

• The AASLD recommends a three‑tiered clinical classification that incorporates the presence or absence of confounding factors and reserves liver biopsy for cases with diagnostic uncertainty or when high‑risk therapies such as corticosteroids are being considered. [19][20]

• Patients are grouped into Probable, Possible, and Definite alcoholic hepatitis:

  • Probable – typical clinical presentation, heavy alcohol use within the prior 60 days, and no confounding factors; biopsy not required.
  • Possible – clinical features present but confounding factors (e.g., concurrent medications, atypical lab values) exist; biopsy is strongly recommended, especially before initiating corticosteroids. [19][20]
  • Definite – clinical diagnosis confirmed by liver biopsy showing macrovesicular steatosis plus at least one of neutrophil infiltration, hepatocyte ballooning, or Mallory‑Denk bodies.

Mandatory Exclusion of Alternative Diagnoses

• Wilson disease must be excluded in younger patients using ceruloplasmin and 24‑hour urine copper testing. 20

Assessment for Acute‑on‑Chronic Liver Failure (ACLF)

• When alcoholic hepatitis is suspected, evaluate for extra‑hepatic organ failures using the CLIF‑SOFA criteria:
  
  • Kidney failure – serum creatinine ≥ 2.0 mg/dL. 20
  • Brain failure – grade III–IV hepatic encephalopathy. 20
  • Circulatory failure – requirement for vasopressor support. 20
  • Respiratory failure – PaO₂/FiO₂ < 200 or need for mechanical ventilation. 20
  • Coagulation failure – INR > 2.5. 20

Role of Liver Biopsy in Cirrhotic Patients

• Transjugular liver biopsy is preferred (over percutaneous) in cirrhotics with coagulopathy or ascites when any of the following apply:
  
  • Atypical laboratory pattern (e.g., AST/ALT ratio < 1.5 or transaminases > 400 IU/mL).
  • Presence of confounding factors (medications, unclear alcohol history).
  • Consideration of corticosteroid therapy for severe disease defined by Maddrey Discriminant Function ≥ 32 or MELD > 20–21. 20
  • Discordant clinical and laboratory findings.

Alcohol History Documentation

• Detailed alcohol consumption should be obtained (typically > 60 g/day for men, > 40 g/day for women) and recent heavy use within the past 60 days is essential for diagnosis.
• Family members should be consulted to corroborate the patient’s alcohol use history. 20

Clinical Algorithm Summary (Evidence‑Based Recommendation)

• Follow a stepwise approach—confirm recent heavy alcohol intake, verify clinical criteria (rapid jaundice, AST > 50 IU/mL, AST/ALT > 1.5, tender hepatomegaly), exclude alternative etiologies, classify according to the three‑tiered system, obtain a transjugular biopsy when indicated, calculate severity scores (mDF, MELD), and assess for ACLF using CLIF‑SOFA. This structured pathway minimizes misclassification and ensures that patients who need biopsy confirmation before initiating potentially toxic therapies receive it. [19][20]

Diagnostic Criteria and Biopsy Considerations for Alcoholic Liver Disease

Alcohol Consumption Thresholds

• A daily alcohol intake exceeding 40 g for men or 20 g for women is a key threshold for diagnosing alcoholic liver disease. 21, 22

Alcohol History Documentation

• The first diagnostic step should be a detailed alcohol‑use history, including recent consumption within the past 60 days and the quantitative thresholds above. 21

Indications for Liver Biopsy

• Liver biopsy is recommended when corticosteroid therapy is being considered for severe alcoholic hepatitis, to confirm the diagnosis before initiating treatment. 21, 22

Biopsy Technique in Patients with Coagulopathy or Ascites

• In patients who have coagulopathy or ascites, a transjugular liver‑biopsy approach is advised to reduce procedural risk. 22

Diagnosis and Management of Alcoholic Hepatitis (Evidence‑Based Summary)

Clinical Diagnostic Criteria

• Heavy alcohol consumption (>40 g/day for men, >20 g/day for women) for ≥6 months, with recent use within the past 60 days, is required for diagnosis【23】.
• Rapid‑onset jaundice (serum bilirubin > 3 mg/dL) developing within 8 weeks of the last drink supports the diagnosis【23】【24】.
• Transaminase pattern of AST > 50 IU/L but rarely >400 IU/L is characteristic【23】.
• An AST/ALT ratio > 1.5 is present in >98 % of histologically confirmed cases; ratios < 1.5 occur in <2 %【24】.

Physical Examination Findings

• Tender hepatomegaly on right‑upper‑quadrant examination is commonly observed【24】.
• Stigmata of chronic liver disease (e.g., spider angiomas, palmar erythema) are present in most patients, indicating underlying cirrhosis【23】【24】.

Laboratory Evaluation and Severity Scoring

• Order a comprehensive metabolic panel (bilirubin, AST, ALT, alkaline phosphatase, albumin, creatinine) to confirm hepatic injury and assess severity【24】.
• Coagulation studies (INR/PT) are required for prognostic scoring【24】.
• Complete blood count often shows neutrophilia; thrombocytopenia suggests cirrhosis【24】.
• Calculate Maddrey Discriminant Function (MDF) and MELD score immediately to stratify mortality risk【23】【24】.

Exclusion of Alternative Etiologies

• Perform abdominal ultrasound (or CT without iodinated contrast) to rule out biliary obstruction【23】【24】.
• Obtain hepatitis A, B, and C serologies to exclude viral hepatitis【24】.
• Test for autoimmune hepatitis (ANA, SMA, IgG) when indicated【24】.
• Screen for drug‑induced liver injury, including acetaminophen use【24】.

Infection Screening Prior to Therapy

• Obtain two sets of blood cultures from separate sites on admission【24】.
• Collect a urine culture with urinalysis【24】.
• Perform diagnostic paracentesis with fluid cell count, culture, and albumin if ascites is present【24】.

Diagnostic Classification Framework (AASLD Consensus)

• Probable alcoholic hepatitis – all clinical criteria met, no confounding factors; liver biopsy not required【24】.
• Possible alcoholic hepatitis – clinical features present but confounded by atypical labs, unclear alcohol history, or hepatotoxic drugs; liver biopsy strongly recommended before corticosteroids【24】.
• Definite alcoholic hepatitis – clinical diagnosis plus histologic confirmation of macrovesicular steatosis with neutrophilic infiltration, ballooning, or Mallory‑Denk bodies【24】【23】.

Indications for Liver Biopsy (Transjugular Preferred)

• Required when confounding factors place the patient in the “possible” category, when AST/ALT < 1.5 or transaminases > 400 IU/L, or when diagnostic uncertainty exists before initiating high‑risk therapy such as corticosteroids【24】.
• Not required for routine diagnosis in typical presentations or for prognostic assessment【24】.

Severity Stratification Scores

• Maddrey Discriminant Function ≥ 32 predicts 40–50 % 90‑day mortality without treatment and triggers consideration of corticosteroids【23】【24】.
• MELD > 20 indicates severe disease with high 90‑day mortality; MELD > 26 warrants evaluation for liver transplantation【23】【24】.
• Glasgow Alcoholic Hepatitis Score ≥ 9 or ABIC category C also identify patients at high short‑term mortality【23】.

Prevalence of Underlying Cirrhosis

• Approximately 70–80 % of patients presenting with alcoholic hepatitis have underlying cirrhosis, identifiable by imaging, laboratory, or clinical stigmata【23】【24】.

Immediate Management Steps (Post‑Diagnosis)

• Enforce absolute alcohol abstinence as the most critical intervention for long‑term survival.
• Initiate aggressive nutritional support (30–40 kcal/kg/day; 1.0–1.5 g protein/kg/day)【23】.
• Administer thiamine 500 mg IV three times daily for 3–5 days before glucose‑containing fluids.
• For severe disease (MDF ≥ 32 or MELD > 20) and after infection has been excluded, start prednisolone 40 mg daily【24】.
• Calculate the Lille score on day 7 of corticosteroid therapy to assess treatment response【24】.